宫瘤消胶囊联合米非司酮治疗子宫肌瘤的临床观察

Clinical observation of Gongliuxiao capsule with mifepristone in the Treatment of uterine myoma

目的:探讨宫瘤消胶囊联合米非司酮治疗子宫肌瘤的临床疗效及安全性。方法:70例子宫肌瘤患者随机分为对照组(34例)及观察组(36例)。对照组采用米非司酮治疗,15mg/次,1次/d,连用3个月。观察组在对照组治疗的基础上给予口服宫瘤消胶囊,3粒/次,3次/d,连用3个月。观察两组治疗前后子宫体积、子宫肌瘤体积、月经量变化情况及检测两组血清促卵泡素(FSH)、黄体生成素(LH)、雌二醇(E2)、孕激素(P)含量,记录两组不良反应发生情况。结果:治疗后,观察组临床痊愈率为38.25%,总有效率为97.06%;对照组临床痊愈率为12.90%,总有效率为70.97%,两组临床痊愈率和总有效率比较,差异均有统计学意义(X2分别为5.387,8.479,P<0.01);观察组子宫体积、子宫肌瘤体积、月经量、血清FSH、LH、E2和P含量水平均低于对照组(P<0.01)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:宫瘤消胶囊联合米非司酮治疗子宫肌瘤疗效和安全性均好,可有效抑制患者性激素分泌,改善患者临床症状和体征。

Objective：To observe the efficacy and safety of Gongliuxiao capsule with mifepristone in the Treatment of uterine myoma.Methods：70 cases of uterine fibroids were randomly divided into control group（34 cases） and observation group（36 cases）. The control group received mifepristone mifepristone,15mg/ time,1 times /d,for 3 months. The observation group in the control group on the basis of the treatment of oral admini-stration of the palace of the oral capsule,3 capsules / times,3 times /d,used for 3 months.Two groups were observed before and after treatment,the uterine volume,uterine fibroids volume,menstruation,serum follicle stimulating hormone（FSH）,luteotropic hormone（LH）,estradiol（E2）,progestin（P）were observed. and the incidence of adverse reactions were recorded. Results：after treatment,the clinical cure rate of 38.25%and the total efficiency was 97.06% in the observation group; the clinical cure rate was 12.90%and the total efficiency of 70.97% in the control group. The difference statistically significant in the two groups. the size of the uterus,uterine fibroid volume,menstrual blood volume,serum FSH,LH,E2 and P in the observation group were lower than control group. There was no significant difference incidence of adverse reactions（P0.05）.Conclusion：Gongliuxiao capsule with mifepristone has good efficacy and safety in the treatment of uterine myoma.it can restrain the secretion of sex hormones index content level,improve symptom and sign.